In this guest blog, Lee Smith and Spiros Servos argue that early-stage biotech leaders who secure investment in 2026 are those who integrate commercial thinking early, aligning science, clinical strategy and market realities into a credible narrative for investors.

Back from our Easter break, we’re hitting the ground running with an update on the publication of agreed text underpinning the UK-US pharmaceuticals agreement.

Lewis Miles discusses changes to EMIs, EISs and VCTs coming into force.

Fermtech has raised £2.5m to scale Koji Cocoa™, a fermentation-based cocoa ingredient made from cocoa shells that delivers 25–33% cost savings and up to 98% lower carbon emissions.

British Growth Partnership Fund I achieves a first close of £200 million, with commitments from Aegon UK, Cushon Master Trust, M&G, and the British Business Bank.